Abstract
All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Current Pharmaceutical Design
Title:Inflammatory Mediators in Epilepsy
Volume: 19 Issue: 38
Author(s): Lourdes Lorigados Pedre, Lilia M Morales Chacón, Sandra Orozco Suárez, Nancy Pavón Fuentes, Bárbara Estupiñán Díaz, Teresa Serrano Sánchez, Iván García Maeso and Luisa Rocha Arrieta
Affiliation:
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Abstract: All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Export Options
About this article
Cite this article as:
Lorigados Pedre Lourdes, Morales Chacón Lilia M, Orozco Suárez Sandra, Pavón Fuentes Nancy, Estupiñán Díaz Bárbara, Serrano Sánchez Teresa, García Maeso Iván and Rocha Arrieta Luisa, Inflammatory Mediators in Epilepsy, Current Pharmaceutical Design 2013; 19 (38) . https://dx.doi.org/10.2174/1381612811319380009
DOI https://dx.doi.org/10.2174/1381612811319380009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High Throughput Screening for Bioactive Components from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders Small Molecule-induced Beta-cell Regeneration from Alternate Cell Sources
Current Tissue Engineering (Discontinued) Strategies of Functional Foods Promote Sleep in Human Being
Current Signal Transduction Therapy Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Genes Involved in Hereditary Hearing Impairment
Current Genomics Hallucinations and Delusions in Children and Adolescents
Current Psychiatry Reviews Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Targeted Nucleic Acid Delivery to Mitochondria
Current Gene Therapy Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Use of Non-steroidal Anti-inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn
Current Drug Metabolism Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Metabotropic Glutamate Receptors Modulate Periaqueductal Grey Descending Analgesic System
Central Nervous System Agents in Medicinal Chemistry Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued)